Trump’s FY27 budget proposes $325M increase for domestic pharma manufacturing

Among the funding priorities for the upcoming fiscal year beginning on October 1, 2026, the Trump administration is proposing several initiatives meant to boost the resiliency and reliability of U.S.-based pharmaceutical manufacturing.

Released earlier this month, President Trump’s Fiscal Year 2027 discretionary budget proposal includes a $325 million increase for the Center for Industrial Base Management and Supply Chain (IBMSC) — within the Administration for Strategic Preparedness and Response (ASPR) — to help bolster domestic pharma manufacturing infrastructure and production of essential medicines.

In August 2025, Trump ordered the Department of Health and Human Services’ ASPR to identify approximately 26 drugs critical to U.S. health and security, secure a six-month supply of active pharmaceutical ingredients (APIs) for the drugs, and prioritize domestic sourcing where possible. 

The order also directed ASPR to update and secure stockpiles for its list of 86 essential medicines, along with a plan to obtain from domestic manufacturers — where possible — and store and maintain a six-month supply of APIs for drugs on the updated list.

U.S.-based pharma manufacturer Bright Path in a Tuesday press release applauded the proposed ASPR/IBMSC funding in the President’s FY27 budget for domestic manufacturing, as the administration looks to strengthen America’s ability to produce essential medicines.

“ASPR and IBMSC understand what it takes to build a domestic pharmaceutical supply chain from the ground up,” Bright Path CEO Tony Quiñones said in a statement. “They’ve been our partners through DARPA, and they’ve seen what this technology can do. This proposed investment would allow them to build on that progress and bring more advanced manufacturing capacity online across the country.”

Under the EQUIP-A-Pharma program, Bright Path is demonstrating its continuous flow manufacturing technology to produce local anesthetic lidocaine HCl and chemotherapy drug carboplatin — two essential medicines on the FDA’s drug shortage list. Announced in 2025, Bright Path’s project is looking to show “enhanced efficiency, scalability, adaptability of the technology, rapid reconfiguration between products with minimal downtime, and a real-time digital approach to generating regulatory submissions.”

Bright Path contends that its manufacturing platform — which leverages the company’s patented Spinning Tube-in-Tube continuous flow reactor technology — produces medicines in less time, at lower cost, and at higher quality than traditional batch approaches, making domestic production cost-competitive with overseas manufacturers. The company has filed Abbreviated New Drug Applications (ANDAs) with the FDA for lidocaine and carboplatin.

In another project under the EQUIP-A-Pharma program, the Mark Cuban Cost Plus Drug Company is integrating AI and machine learning for real-time quality assessment and process optimization designed to process APIs and finished medication doses “rapidly with in-line metrology (precise measurement) to produce lidocaine, a widely used anesthetic, and diltiazem, a calcium channel blocker used to treat heart conditions.”

FDA and pharma manufacturing 

Trump’s FY27 budget submission for the FDA proposes $9 million and 19 new full-time positions to accelerate advanced pharmaceutical manufacturing. The funds are meant to support approaches to streamline Chemistry, Manufacturing, and Controls (CMC) reviews while funding the FDA’s new PreCheck program, which is intended to provide earlier and more frequent interaction between drug manufacturers and the agency on facility design and construction.

“Initiatives include accelerating review and approval by supporting the Commissioner’s National Priority Voucher program and developing science- and risk-based approaches to streamline CMC reviews,” the budget proposal states. “It will also fund FDA PreCheck, a two-phase initiative proposed to accelerate the establishment of new or advanced pharmaceutical manufacturing facilities in the United States, strengthening the domestic drug supply chain.”

Bright Path in its press release made the case that the current regulatory framework for generic drug approvals is based on traditional batch-based manufacturing and does not fully accommodate the speed, flexibility, and process advantages achievable through advanced manufacturing technologies such as continuous flow production.

“While FDA has made important progress through programs like the Emerging Technology Program, in which Bright Path is an active participant, additional investment is needed by the agency to further develop regulatory models that keep pace with the technology,” the company said.

Bright Path encouraged the FDA to modernize approval pathways for continuous manufacturing, including merging the advanced review concepts already applied to New Drug Applications (NDAs) with the ANDA review process.

“Doing so would help ensure that the regulatory framework supports, rather than delays, the domestic manufacturing capacity that both the tariffs and these proposed investments are designed to create,” according to Bright Path.